2022年WHO分类对嗜酸细胞性和滤泡性甲状腺癌重新分类的影响
该回顾性研究纳入2000至2016年在荷兰伊拉斯姆斯医学中心治疗的52例嗜酸细胞性甲状腺癌(OTC)和89例滤泡性甲状腺癌(FTC)成人患者,由2名独立病理学家依据2004年和2022年WHO分类重新评估肿瘤。2022年WHO分类将OTC和FTC分为微小浸润、包裹性血管浸润和广泛浸润三类,较2004版显著改善了两亚型疾病特异性生存的风险分层,FTC的放射性碘难治性疾病也呈类似趋势。
要点
- 2022年WHO分类将OTC和FTC分为微小浸润、包裹性血管浸润和广泛浸润三类。
- 52例OTC中15例(28.8%)、89例FTC中34例(38.2%)被重新分类为包裹性血管浸润型。
- 2022版分类较2004版显著改善两亚型疾病特异性生存的风险分层。
核心结论
- 按2022年WHO分类将OTC和FTC分为3个亚类,显著改善了低、中、高风险患者之间的区分,尤其是对疾病特异性生存和放射性碘难治性疾病的区分。
研究设计与样本
- 回顾性纳入2000至2016年在荷兰伊拉斯姆斯医学中心治疗的52例OTC和89例FTC成人患者。
- 所有肿瘤由2名独立病理学家借助荷兰病理数据库(Palga)进行广泛复核。
- 采用Kaplan-Meier曲线分析2004年和2022年WHO分类与总生存、疾病特异性生存、无复发生存及放射性碘难治性疾病的关联。
主要发现
- 52例OTC中15例(28.8%)、89例FTC中34例(38.2%)被重新分类为包裹性血管浸润型OTC或FTC。
- 2022年WHO分类较2004版显著改善了两亚型疾病特异性生存的风险分层。
- OTC的10年疾病特异性生存率:微小浸润型100%、包裹性血管浸润型92.9%、广泛浸润型56.5%;2004版分类下微小浸润型100%、广泛浸润型64.2%。
- FTC的放射性碘难治性疾病也观察到类似趋势。
关键数值与推荐
- 2022年WHO分类依据包膜和血管浸润程度将OTC和FTC分为微小浸润、包裹性血管浸润和广泛浸润肿瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2022 WHO Classification categorizes oncocytic (OTC) and follicular thyroid carcinoma (FTC), based on the degree of capsular and vascular invasion, into minimally invasive (MI), encapsulated angio-invasive (EA), and widely invasive tumors (WI). While associations with clinical outcomes have been studied extensively in FTC, robust clinical data are lacking for OTC. We aimed to investigate the impact of the reclassification of OTC and FTC by the 2022 WHO Classification on clinical outcomes. METHODS: All adult OTC and FTC patients treated at the Erasmus MC (the Netherlands) between 2000 and 2016 were retrospectively included. All tumors were extensively revised by 2 independent pathologists, facilitated by Palga: Dutch Pathology Databank. Kaplan-Meier curves were used to study the association of the 2004 and 2022 WHO Classification with overall survival, disease-specific survival (DSS), recurrence-free survival, and radioactive iodine (RAI)-refractory disease. RESULTS: Among 52 OTC and 89 FTC patients, 15 (28.8%) OTC and 34 (38.2%) FTC tumors were reclassified as EAOTC or EAFTC. The 2022 WHO Classification substantially improved risk stratification in both subtypes for DSS, compared to the 2004 edition. Ten-year DSS rates were 100% for MIOTC, 92.9% for EAOTC, and 56.5% for WIOTC, compared to 100% (MIOTC) and 64.2% (WIOTC) following the 2004 WHO Classification. For FTC and RAI-refractory disease, similar trends were observed. CONCLUSION: Classification of OTC and FTC into 3 subcategories as defined by the 2022 WHO Classification substantially improves discrimination between low-, intermediate-, and high-risk patients, especially for DSS and RAI-refractory disease.
引用
- Stegenga MT, Oudijk L, van Velsen EFS, et al. Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification. J Clin Endocrinol Metab. 2025. PMID: 39166490. doi:10.1210/clinem/dgae581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。